Global Health Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Global Health has allotted 61,500 equity shares under ESOP on 22 April 2026. Post allotment, the paid up equity share capital has increased to Rs. 53,77,03,764/- divided into 26,88,51,882 equity shares of Rs. 2/- each.

The board of directors of the company, at the meeting held today, approved the execution of definitive agreements to enter into a built-to-suit and lease arrangement, with Shripal Hospitality and others, to establish a super speciality hospital in Varanasi.

Under this arrangement, the civil infrastructure of the hospital will be developed by the partner in line with Medanta?s specifications, while Medanta will undertake investments towards interior services, fit outs and medical equipment.

The total investment by Medanta is estimated at approximately Rs. 550 crore.

The proposed hospital will be developed on a strategically located freehold land parcel in central Varanasi and is expected to cater to a population base of over 4 million in the city and adjoining regions.

The hospital will deliver advanced clinical care through a combination of world-class medical expertise, cutting-edge technology, and a comprehensive multi-specialty offering.

This expansion marks a continued commitment by Medanta to deepen its presence in Uttar Pradesh, following the successful establishment of its 950-bed flagship hospital in Lucknow and recently inaugurated 550-bed hospital in Noida.

Global Health is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India.

On a consolidated basis, Global Health's net profit declined 33.51% to Rs 95.02 crore while net sales rose 18.83% to Rs 1121.05 crore in Q3 December 2025 over Q3 December 2024.

Recently, a domestic brokerage maintained a 'buy? rating on the stock and set a target price of Rs 1,382.

The brokerage cited improving earnings visibility, margin expansion tailwinds and a more reasonable valuation backdrop as key drivers for its positive stance. The research house expects the company's revenue, EBITDA and profit after tax to grow at a CAGR of 14%, 26% and 32%, respectively, over FY26 to FY28.

Powered by Capital Market - Live News

The brokerage cited improving earnings visibility, margin expansion tailwinds and a more reasonable valuation backdrop as key drivers for its positive stance.

It noted that the stock has corrected sharply over the past six months due to concerns around the Noida greenfield facility and geopolitical tensions in the Middle East, but expects these factors to normalise in the coming quarters.

The brokerage highlighted that the company has limited exposure of about 2% of sales to Middle East patients, which can be offset by domestic demand and inflows from other geographies.

Operationally, the company continues to show steady growth, supported by strong performance at its Gurugram facility and improving occupancy levels across its network, which are trending toward 60% as newer assets scale up.

It also pointed to Medanta?s strong positioning in quaternary care, supporting robust average revenue per patient, comparable with peers such as Max Healthcare.

The company is expanding capacity, with plans to increase its bed count to around 6,382 by FY29 from 3,579 currently, which is expected to drive operating leverage and margin expansion.

The brokerage expects revenue, EBITDA and profit after tax to grow at a CAGR of 14%, 26% and 32%, respectively, over FY26 to FY28.

Global Health is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India.

On a consolidated basis, Global Health's net profit declined 33.51% to Rs 95.02 crore while net sales rose 18.83% to Rs 1121.05 crore in Q3 December 2025 over Q3 December 2024.

PAT was impacted by Noida hospital depreciation and finance cost in addition to initial operating losses. Additionally, PAT was further impacted due to statutory impact of new Labour Codes which is non-recurring in nature and classified as exceptional Items amounting to Rs 36.6 crore in Q3 FY26.

Powered by Capital Market - Live News

Global Health has received a communication from NSE Sustainability Ratings & Analytics informing that they have assigned an ESG rating of '69' for the Financial Year 2025 to the Company.

Powered by Capital Market - Live News